HMGN2P24: A Potential Drug Target for Nucleosome Dynamics and DNA Replication

Target Name: HMGN2P24

NCBI ID: G729505

HMGN2P24

Other Name(s): High mobility group nucleosomal binding domain 2 pseudogene | high mobility group nucleosomal binding domain 2 pseudogene 24

HMGN2P24: A Potential Drug Target for Nucleosome Dynamics and DNA Replication

High mobility group nucleosomal binding domain (HMGN2) is a gene that encodes a protein known as HMGN2P24. The HMGN2P24 protein is a key component of the nucleosome, which is the basic unit of chromatin. The nucleosome plays a crucial role in the regulation of gene expression, DNA replication, and repair, and is composed of several key components, including the histone proteins H1A, H2A, H3A, and H4A, as well as the non-histone proteins p16 and p21.

HMGN2P24 is a 21-kDa protein that is expressed in a variety of tissues and cells, including muscle, liver, and brain. It is localized to the nucleosome and is involved in the regulation of chromatin structure and stability.

Drug targeting and biomarkers

Drug targeting is the process of using small molecules or antibodies to selectively bind to and inhibit the activity of a specific protein, such as HMGN2P24. This process is used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

HMGN2P24 is an attractive drug target due to its unique structure and its involvement in the regulation of nucleosome dynamics and stability. Its HMN2P24 protein is involved in the regulation of the distribution of nucleosomes along the DNA double helix, and is thought to play a role in the regulation of chromatin accessibility and gene expression.

In addition, HMGN2P24 has also been shown to be involved in the regulation of DNA replication and repair, which are critical processes for the growth and maintenance of damaged DNA. Its involvement in these processes makes it an attractive target for drugs that are used to treat cancer and other diseases that are characterized by DNA damage.

Antibodies against HMGN2P24 have been shown to be effective in inhibiting the activity of the protein and are being evaluated as potential biomarkers for a variety of diseases. For example, studies have shown that antibodies against HMGN2P24 can be used to treat neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

HMGN2P24 is a protein that is involved in the regulation of nucleosome dynamics and stability, and is a potential drug target for a variety of diseases. Its unique structure and its involvement in the regulation of DNA replication and repair make it an attractive target for antibodies and small molecules. Further research is needed to fully understand the role of HMGN2P24 in the regulation of nucleosome dynamics and to develop effective treatments for diseases that are characterized by DNA damage.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 24

The "HMGN2P24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets